AGA Defines When Cancer Surveillance Should Stop in Older Adults: CGH | October 2026

What Did the Guidance Recommend?

The AGA recommends moving beyond chronological age when deciding whether to continue pancreatic-cyst or hepatocellular-carcinoma surveillance. Patients with substantial comorbidity—an age-adjusted Charlson index of approximately 3–5 or higher—who would not undergo pancreatic surgery should generally be counselled against continued surveillance.

For a patient older than 65 years, surveillance cessation can be considered when a pancreatic cyst is ≤15 mm, has remained stable for five years and has no worrisome features or high-risk stigmata. For patients older than 75, the same discussion is appropriate for stable cysts <30 mm. Concerning growth remains at least 3 mm annually or 6 mm over two years.

HCC surveillance should continue in older adults with cirrhosis when potentially beneficial treatment remains realistic; age alone is not a reason to stop. Conversely, surveillance should generally cease when estimated life expectancy is under one to two years, including Child–Pugh C cirrhosis when transplantation is not an option. pubmed.ncbi.nlm.nih.gov

Why Does It Matter?

Surveillance is valuable only when detecting cancer can lead to meaningful treatment. The advice offers practical stopping thresholds, but it is expert guidance without formal systematic review or GRADE assessment.

GastroAGI Takeaway

Before ordering another surveillance scan, ask whether the patient could benefit from—and would accept—the intervention that a positive finding would trigger.